mRNA vaccines: the most recent clinical applications of synthetic mRNAopen access
- Kwon, Suji; Kwon, Minseon; Im, Seongeun; Lee, Kyuri; Lee, Hyukjin
- Issue Date
- PHARMACEUTICAL SOC KOREA
- In vitro transcribed (IVT) mRNA; mRNA vaccines
- ARCHIVES OF PHARMACAL RESEARCH, v.45, no.4, pp.245 - 262
- Journal Title
- ARCHIVES OF PHARMACAL RESEARCH
- Start Page
- End Page
- Synthetic mRNA has been considered as an emerging biotherapeutic agent for the past decades. Recently, the SARS-CoV-2 pandemic has led to the first clinical use of synthetic mRNA. mRNA vaccines showed far surpassing influences on the public as compared to other vaccine platforms such as viral vector vaccines and recombinant protein vaccines. It allowed rapid development and production of vaccines that have never been achieved in history. Synthetic mRNA, called in vitro transcribed (IVT) mRNA, is the key component of mRNA vaccines. It has several advantages over conventional gene-expressing systems such as plasmid DNA and viral vectors. It can translate proteins in the cytoplasm by structurally resembling natural mRNA and exhibit various protein expression patterns depending on how it is engineered. Another advantage is that synthetic mRNA enables fast, scalable, and cost-effective production. Therefore, starting with the mRNA vaccine, synthetic mRNA is now in the spotlight as a promising new drug development agent. In this review, we will summarize the latest IVT mRNA technology such as new mRNA structures or large-scale production. In addition, the nature of the innate immunogenicity of IVT mRNA will be discussed along with its roles in the development of vaccines. Finally, the principles of the mRNA vaccine and the future direction of synthetic mRNA will be provided.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 약학대학 > 약학과 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.